Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Evidence Synthesis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
ReportPublication 2017DCP3: Injury Prevention and Environmental Health
This report from the World Bank is the seventh volume of the Disease Control Priorities, …
This report from the World Bank is the seventh volume of the Disease Control Priorities, Third Edition (DCP3) series and focuses on injury prevention and environmental health. The burden of death and disability resulting from interpersonal violence, road traffic injuries, unintentional injuries, occupational health risks, and climate and pollution falls disproportionately on low- and middle- income countries. This report examines risk factors and offers an economic analysis of platforms to deliver cost-effective interventions to prevent…
Evidence Synthesis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Injuries/Accidents | Environmental Health | Policy/Regulation | Global Governance | Climate/Environment | Culture/Society | Economics/Finance | Health/Medicine | Global -
ReportPublication 2017Economic Value of Informal Mental Health Caring
Caregivers, family and friends play a significant role in supporting people with mental illness, and …
Caregivers, family and friends play a significant role in supporting people with mental illness, and it has long been recognized that informal carers constitute a significant ‘hidden’ workforce in Australia. Faced as Australia is with an ageing population and burgeoning chronic disease, data on the contribution that carers make and the consequent savings to governments and other ‘payers’ need to be articulated. This report attempts to put a ‘value’ on informal caring for those with mental illness.…
Preferences/Values | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Chronic Disease/Risk | Mental Health | Health Systems | Economics/Finance | Health/Medicine | Oceania -
ReportPublication 2015Modeling to Improve Policy Decisions in the Americas: Noncommunicable Diseases
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only …
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only to human health, but also to a country’s economic development and growth. The evidence on both of these counts is compelling. In 2012, cardiovascular disease, diabetes, cancers, chronic respiratory conditions including asthma, and other NCDs were the cause of 4.5 million deaths in the Americas. Of that total number, 1.5 million of them were premature, occurring among people aged 30-69…
Microsimulation | Cost-Effectiveness Analysis | Decision Analysis | Priority Setting/Ethics | Costing Methods | Mathematical Models | State-Transition | Chronic Disease/Risk | Mental Health | Health/Medicine | Latin America & Caribbean -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Evidence Synthesis | Preferences/Values | Cost-Effectiveness Analysis | Health Outcomes | Technology Assessment | Chronic Disease/Risk | Mental Health | Health Systems | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology | North America -
GuidelinesPublication 2014EPA Guidelines for Preparing Economic Analyses
The US Environmental Protection Agency (EPA) Guidelines for Preparing Economic Analyses provide a framework for …
The US Environmental Protection Agency (EPA) Guidelines for Preparing Economic Analyses provide a framework for assessing the impacts of environmental regulations and policies that has been extensively peer-reviewed and is widely-applied both within and outside of the agency. The Guidelines discuss: (1) statutory and executive order requirements for conducting economic analyses; (2) identifying the need for policy action; (3) regulatory and non-regulatory approaches to pollution control; (4) baseline definition; (5) discounting future benefits and costs;…
Preferences/Values | Benefit-Cost Analysis | Decision Analysis | Priority Setting/Ethics | Environmental Health | Policy/Regulation | Climate/Environment | Government/Law | North America | Critical Thinking/Analysis -
GuidelinesPublication 2012Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Task Force-1
This paper provides an overview of the work of the joint Task Force between the …
This paper provides an overview of the work of the joint Task Force between the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM), provides the overarching recommendations, and discusses future work that is needed. The audience for these papers includes anyone who build models, stakeholders who utilize their results, and those concerned with the use of models to support decision making. This article is part 1 of…
Microsimulation | Decision Analysis | Calibration/Validation | Costing Methods | Health Outcomes | Value of Information | Mathematical Models | State-Transition | Dynamic Transmission | Dynamic Simulation | Infectious Diseases | Health/Medicine -
ReportPublication 2023Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health
This ISPOR Task Force report examines the integration of patient preferences into healthcare decision-making, emphasizing …
This ISPOR Task Force report examines the integration of patient preferences into healthcare decision-making, emphasizing the growing significance of both qualitative and quantitative methods for studying these preferences. The report synthesizes current best practices to enhance the utility and impact of patient-preference studies. The methods involved reviewing existing literature and practices to construct the ISPOR Roadmap for Patient Preferences in Decision Making. This roadmap encourages collaboration among researchers, decision-makers, patients, patient groups, and other stakeholders.…
Evidence Synthesis | Preferences/Values | Health Outcomes | Health/Medicine -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Preferences/Values | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Government/Law | North America